Some GLP-1 medicines lower the chance of major cardiovascular events in the people studied. The benefit depends on which medicine was tested, which events were counted, and who was in the trial. A headline such as “20% lower cardiovascular risk” starts to make sense when you can see how many people had an event in each group and over how much time.
Which events did the trial count?
Three-part MACE, or major adverse cardiovascular events, usually combines cardiovascular death, nonfatal heart attack, and nonfatal stroke. A trial can compare how long it takes people in each group to have a first event of any of these kinds. The combined outcome gives the researchers more events to study. A result for the combined outcome does not tell you that each event fell by the same amount.
For example, SELECT demonstrated a reduction in its primary three-part composite. Cardiovascular death alone was the first outcome in an ordered set of additional statistical tests, and superiority for that outcome was not confirmed. “Fewer people had one of these three events” is the claim the main result supports. Hospitalization for heart failure is a separate endpoint, as are blood pressure, pulse, and cholesterol measurements. Wegovy prescribing information, section 14.1.
How do you compare the event rates?
| Trial and treatment comparison | People enrolled | Participants with a primary event | Follow-up |
|---|---|---|---|
| SELECT: weekly semaglutide injection versus placebo | Adults aged 45 or older with established cardiovascular disease, overweight or obesity, and no diabetes | 569/8,803 (6.5%) versus 701/8,801 (8.0%) | Mean 39.8 months |
| LEADER: liraglutide versus placebo | Adults with type 2 diabetes and high cardiovascular risk | 608/4,668 (13.0%) versus 694/4,672 (14.9%) | Median 3.8 years |
| SURPASS-CVOT: tirzepatide versus dulaglutide | Adults with type 2 diabetes and atherosclerotic cardiovascular disease | 801/6,586 (12.2%) versus 862/6,579 (13.1%) | Median 4 years |
Each trial used the three-event composite above. The populations, timeframes, and comparison treatments differ. The valid first comparison is across each row. For example, a 6.5% event rate in SELECT and a 13.0% event rate in LEADER do not tell you which prescription is more protective. SELECT, LEADER, and SURPASS-CVOT trial reports.
How can “20% lower” and “1.5 points lower” both be right?
In SELECT, 8.0% minus 6.5% is 1.5 percentage points. Using the rounded trial proportions, that's about 15 fewer people per 1,000 with a first major event over about 40 months. This is the observed absolute difference in that population.
The 20% comes from a hazard ratio of 0.80. That statistical comparison takes account of when events occurred during follow-up. It describes a lower rate of having an event among people still at risk as the trial ran. Subtracting the percentages tells you how many people had an event over the trial. The two calculations give different views of the same comparison. If your starting cardiovascular risk is different from the trial participants' risk, the trial's absolute difference is unlikely to be your exact benefit.
What changes when both groups get an active treatment?
SURPASS-CVOT tested tirzepatide against dulaglutide, a medicine with prior cardiovascular outcomes evidence. Tirzepatide met the prespecified noninferiority criterion, meaning the trial ruled out being worse than dulaglutide by the margin the researchers had set in advance. The hazard ratio was 0.92 (95.3% confidence interval 0.83–1.01). The superiority test did not establish that tirzepatide reduced events more than dulaglutide. Their observed percentages were close, and the trial does not provide a direct estimate of tirzepatide versus placebo.
Does a trial result fit your prescription?
Start with the exact product and reason for prescribing it. The current U.S. Wegovy label covers reducing MACE in adults with established cardiovascular disease and overweight or obesity, with diet and physical activity. It covers injection and tablets for this indication. The SELECT numbers in the table come from the injection trial. Wegovy HD's 7.2 mg dose is a weight-management dose, with different labeling from the cardiovascular maintenance doses. FDA tablet review.
The Mounjaro label covers adults with type 2 diabetes at high risk of MACE. SURPASS-CVOT directly studied people with type 2 diabetes and established atherosclerotic cardiovascular disease. Both details matter when a study population and the label use different wording. Zepbound's label has no matching cardiovascular event reduction indication, even though it also contains tirzepatide.
If you've had a heart attack or stroke and have overweight or obesity, ask how the evidence for preventing another event fits your treatment plan. If your question is preventing a first event and you have no established cardiovascular disease, ask what evidence applies to your history before borrowing the 15-per-1,000 figure from SELECT. Bring your diagnosis, diabetes status and medication list. The answer may depend on risks that a weight change or a cholesterol result by itself cannot describe. For those measurements, see our guides to semaglutide and heart rate and Mounjaro and cholesterol.

About the author
Maya Lee
Glowise Senior GLP-1 Content Editor
Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.
She helps readers ask better questions and keep the details relevant to a care conversation together.
See more Glowise on Google
Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.



